• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation.舒张性血压 J 型曲线的发生机制:亚临床心肌损伤和免疫激活。
Int J Cardiol. 2019 Feb 1;276:255-260. doi: 10.1016/j.ijcard.2018.09.028. Epub 2018 Sep 8.
2
Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.可溶性尿激酶型纤溶酶原激活物受体水平是冠状动脉疾病的存在、严重程度及未来不良事件的独立预测指标。
J Am Heart Assoc. 2014 Oct 23;3(5):e001118. doi: 10.1161/JAHA.114.001118.
3
SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.可溶性尿激酶型纤溶酶原激活物受体(SuPAR)与疑似冠心病患者的死亡和不良心血管结局相关。
Scand Cardiovasc J. 2020 Dec;54(6):339-345. doi: 10.1080/14017431.2020.1762917. Epub 2020 May 13.
4
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.心血管-肾脏生物标志物可溶性尿激酶型纤溶酶原激活物受体与冠心病患者心血管死亡和心肌梗死相关,与肌钙蛋白、C 反应蛋白和肾功能无关。
J Am Heart Assoc. 2020 Apr 21;9(8):e015452. doi: 10.1161/JAHA.119.015452. Epub 2020 Apr 17.
5
Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.可溶性尿激酶型纤溶酶原激活物受体(suPAR)介导受教育程度较低对冠心病患者不良结局的影响。
Eur J Prev Cardiol. 2024 Mar 27;31(5):521-528. doi: 10.1093/eurjpc/zwad311.
6
Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.可溶性尿激酶型纤溶酶原激活物受体和高敏肌钙蛋白水平预测非阻塞性冠状动脉疾病的结局。
J Am Heart Assoc. 2020 Apr 21;9(8):e015515. doi: 10.1161/JAHA.119.015515. Epub 2020 Apr 17.
7
Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.循环可溶性尿激酶型纤溶酶原激活物受体水平与外周动脉疾病结局的关系。
Atherosclerosis. 2017 Sep;264:108-114. doi: 10.1016/j.atherosclerosis.2017.06.019. Epub 2017 Jun 8.
8
Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.预测伴有 2 型糖尿病的非裔美国人的死亡率:可溶性尿激酶型纤溶酶原激活物受体、冠状动脉钙和高敏 C 反应蛋白。
J Am Heart Assoc. 2018 May 1;7(9):e008194. doi: 10.1161/JAHA.117.008194.
9
Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.血浆可溶性尿激酶型纤溶酶原激活物受体水平与非阻塞性冠状动脉疾病患者的冠状动脉微血管功能独立相关。
Atherosclerosis. 2015 Mar;239(1):55-60. doi: 10.1016/j.atherosclerosis.2014.12.025. Epub 2014 Dec 20.
10
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.在心血管风险增加的高血压患者治疗中无J型曲线证据:VALUE试验
Blood Press. 2016;25(2):83-92. doi: 10.3109/08037051.2015.1106750. Epub 2015 Oct 29.

引用本文的文献

1
Systolic and Diastolic Blood Pressure, Cardiac Biomarkers, and Cardiovascular Mortality in Adults Without Cardiovascular Disease.无心血管疾病成年人的收缩压与舒张压、心脏生物标志物及心血管死亡率
JACC Adv. 2025 Mar 27;4(5):101678. doi: 10.1016/j.jacadv.2025.101678.
2
Sex Differences in Achieved Diastolic Blood Pressure and Cardiovascular Outcomes in Elderly Patients With Hypertension.老年高血压患者舒张期血压达标情况及心血管结局的性别差异
JACC Adv. 2025 Apr;4(4):101675. doi: 10.1016/j.jacadv.2025.101675. Epub 2025 Mar 20.
3
Non-linear association and benchmark dose of blood pressure on carotid artery intima-media thickening in a general population of southern China.中国南方普通人群中血压与颈动脉内膜中层厚度的非线性关联及基准剂量
Front Cardiovasc Med. 2024 May 13;11:1325947. doi: 10.3389/fcvm.2024.1325947. eCollection 2024.
4
Unsolved Problem: (Isolated) Systolic Hypertension with Diastolic Blood Pressure below the Safety Margin.未解决的问题:(孤立性)收缩期高血压伴舒张压低于安全范围。
Med Princ Pract. 2020;29(4):301-309. doi: 10.1159/000508462. Epub 2020 May 7.

本文引用的文献

1
Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control.基础舒张压对强化与标准血压控制效果影响的研究。
Circulation. 2018 Jan 9;137(2):134-143. doi: 10.1161/CIRCULATIONAHA.117.030848. Epub 2017 Oct 11.
2
Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.循环可溶性尿激酶型纤溶酶原激活物受体水平与外周动脉疾病结局的关系。
Atherosclerosis. 2017 Sep;264:108-114. doi: 10.1016/j.atherosclerosis.2017.06.019. Epub 2017 Jun 8.
3
The J-shaped Curve for Blood Pressure and Cardiovascular Disease Risk: Historical Context and Recent Updates.血压与心血管疾病风险的J形曲线:历史背景与近期进展
Curr Atheroscler Rep. 2017 Aug;19(8):34. doi: 10.1007/s11883-017-0670-1.
4
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.在高危患者中实现血压和心血管结局:ONTARGET 和 TRANSCEND 试验结果。
Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.
5
Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.可溶性尿激酶型纤溶酶原激活物受体可改善慢性心力衰竭患者的风险预测。
JACC Heart Fail. 2017 Apr;5(4):268-277. doi: 10.1016/j.jchf.2016.12.008.
6
High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease.高敏心肌肌钙蛋白、他汀类药物治疗与冠心病风险
J Am Coll Cardiol. 2016 Dec 27;68(25):2719-2728. doi: 10.1016/j.jacc.2016.10.020.
7
Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.根据稳定型冠状动脉疾病患者的收缩压和舒张压达标情况评估心血管事件发生率和死亡率:一项国际队列研究。
Lancet. 2016 Oct 29;388(10056):2142-2152. doi: 10.1016/S0140-6736(16)31326-5. Epub 2016 Aug 30.
8
Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.舒张压、亚临床心肌损伤与心脏事件:对血压控制的启示
J Am Coll Cardiol. 2016 Oct 18;68(16):1713-1722. doi: 10.1016/j.jacc.2016.07.754. Epub 2016 Aug 30.
9
Blood Pressure Is a Major Modifiable Risk Factor Implicated in Pathogenesis of Intraplaque Hemorrhage: An In Vivo Magnetic Resonance Imaging Study.血压是斑块内出血发病机制中一个主要的可改变风险因素:一项体内磁共振成像研究。
Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):743-9. doi: 10.1161/ATVBAHA.115.307043. Epub 2016 Feb 4.
10
Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry.脉压与动脉粥样硬化血栓形成患者心血管事件的风险:来自 REACH 登记研究。
J Am Coll Cardiol. 2016 Feb 2;67(4):392-403. doi: 10.1016/j.jacc.2015.10.084.

舒张性血压 J 型曲线的发生机制:亚临床心肌损伤和免疫激活。

Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation.

机构信息

Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, United States of America.

Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, United States of America.

出版信息

Int J Cardiol. 2019 Feb 1;276:255-260. doi: 10.1016/j.ijcard.2018.09.028. Epub 2018 Sep 8.

DOI:10.1016/j.ijcard.2018.09.028
PMID:30217423
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6324952/
Abstract

BACKGROUND

Low diastolic blood pressure (DBP) is associated with increased risk of cardiovascular events. In patients with coronary artery disease (CAD), limitations in coronary blood flow and immune activity are implicated mechanisms, but evidence is lacking. We investigated the association between DBP, biomarkers of myocardial injury, inflammation, immune activation and incident events in patients with CAD.

METHODS

We studied 2448 adults (mean age 65 ± 12 years, 68% male, median follow-up 4.5 years) with CAD. DBP was categorized into 10 mm Hg increments. Biomarkers of myocardial injury (high sensitivity cardiac troponin-I [hs-cTnI]) and immune activity/inflammation (soluble urokinase plasminogen activator receptor [suPAR]) were dichotomized at their median values. DBP 70-79 mm Hg was used as the referent group, and individuals were followed prospectively for adverse outcomes.

RESULTS

After adjusting for demographic and clinical covariates, individuals with DBP < 60 mm Hg had increased odds of elevated levels of hs-cTnI (OR = 1.68; 95% CI = 1.07, 2.65) and suPAR (OR = 1.71; 95% CI = 1.10, 2.65) compared to the referent group. Additionally, DBP < 60 mm Hg was associated with increased adjusted risk of cardiovascular death or MI (HR = 2.04; 95% CI = 1.32, 3.16) and all-cause mortality (HR = 2.41; 95% CI = 1.69, 3.45).

CONCLUSION

In patients with CAD, DBP < 60 mm Hg is associated with subclinical myocardial injury, immune/inflammatory dysregulation and incident events. Aggressive BP control may be harmful in these patients, and further investigation is warranted to determine appropriate BP targets in patients with CAD.

摘要

背景

舒张压(DBP)较低与心血管事件风险增加有关。在患有冠状动脉疾病(CAD)的患者中,冠状动脉血流受限和免疫活性被认为是潜在机制,但缺乏证据。我们研究了 DBP 与 CAD 患者心肌损伤、炎症、免疫激活和事件发生的生物标志物之间的关系。

方法

我们研究了 2448 名成年人(平均年龄 65±12 岁,68%为男性,中位随访时间为 4.5 年),他们患有 CAD。DBP 分为 10mmHg 递增。心肌损伤的生物标志物(高敏心肌肌钙蛋白 I [hs-cTnI])和免疫活性/炎症的生物标志物(可溶性尿激酶型纤溶酶原激活物受体 [suPAR])以中位数为界分为两类。DBP 70-79mmHg 为参照组,前瞻性随访观察不良结局。

结果

在调整人口统计学和临床协变量后,DBP<60mmHg 的个体发生 hs-cTnI 水平升高(OR=1.68;95%CI=1.07,2.65)和 suPAR 水平升高(OR=1.71;95%CI=1.10,2.65)的几率高于参照组。此外,DBP<60mmHg 与心血管死亡或心肌梗死(HR=2.04;95%CI=1.32,3.16)和全因死亡率(HR=2.41;95%CI=1.69,3.45)的调整风险增加相关。

结论

在 CAD 患者中,DBP<60mmHg 与亚临床心肌损伤、免疫/炎症失调和事件发生有关。在这些患者中,积极的血压控制可能有害,需要进一步研究以确定 CAD 患者的适当血压目标。